Released: · Last reviewed:
Semaglutide is administered as a once-weekly subcutaneous injection. The standard titration schedule increases the dose every 4 weeks to minimize gastrointestinal side effects.
Standard schedule: Week 1-4 at 0.25 mg, Week 5-8 at 0.5 mg, Week 9-12 at 1.0 mg, Week 13-16 at 1.7 mg, Week 17+ at 2.4 mg (maintenance). Each dose level is held for at least 4 weeks before considering escalation. The 0.25 mg starter dose is intended for tolerance only and is not therapeutic. Patients who tolerate well may reach maintenance at 16 weeks; patients who experience significant side effects may take longer or stay at a lower maintenance dose. Injection sites: abdomen, thigh, or upper arm — rotated weekly.
NexLife is structured around clinical best practices for semaglutide. See full NexLife review.
Compounded semaglutide · clinician oversight
*12-month plan · flat rate · all titration doses
Or call (949) 818-8000
Citations supporting clinical and regulatory statements on this page. External links open in a new tab.